Results 151 to 160 of about 5,526 (234)

Role of metabolic reprogramming and lactylation in diabetic nephropathy: molecular mechanisms and therapeutic prospects - a narrative review. [PDF]

Front Endocrinol (Lausanne)
Li Z, Wang Y, Fang D, Ye W, Zhang X, Chen Z.   +5 more
europepmc   +1 more source

Histone lactylation modification and its role in cerebral ischemia-reperfusion injury (Review). [PDF]

Biomed Rep
Tao J, Xu J, Zhou L.
europepmc   +1 more source

Lactylation in urological malignancies: emerging mechanisms and therapeutic direction. [PDF]

Front Cell Dev Biol
Lin J, Yuan C, Liu C, Zhang M, Luo J, Wu Z, Ma Q, Xie S, Liang Y, Chen G.   +9 more
europepmc   +1 more source

Epigenetic Changes Associated With Obesity-related Metabolic Comorbidities [PDF]

Obesity arises from a complex interaction of genetic, hormonal, dietary, and behavioral factors that drive chronic energy imbalance, excessive fat accumulation, systemic inflammation, and insulin resistance, thus increasing the risk of metabolic diseases.

core   +1 more source

Lactate metabolism and protein lactylation in colorectal cancer: from metabolic reprogramming to epigenetic regulation. [PDF]

Front Oncol
Song Y, Zou M, Wu S, Ren R, Yuan S, Pan Y, Pan J.   +6 more
europepmc   +1 more source

ACSS2: Tumor-promoting lactyl-CoA synthetase that drives histone lactylation

hLife
Katherine L. Wang, Zhongsheng You
openaire   +2 more sources

Mechanisms of lactylation modification in hepatocellular carcinoma treatment resistance. [PDF]

Gastroenterol Rep (Oxf)
Zhu Y, Wang Z, Xi H, Lu W, Sun M, Lin X.
europepmc   +1 more source

Protein lactylation in metabolic dysfunction-associated steatotic liver disease: a mechanistic review. [PDF]

Diabetol Metab Syndr
Chen H, Ye Y, He T, Li B, Wang Q.
europepmc   +1 more source

Lactylation in colorectal cancer: Unveiling novel mechanisms in metabolism, progression and therapeutic targeting. [PDF]

Clin Transl Med
Liu M, Li W, Ji Y, Chen Y, Wei G, Huo J, Gui T.   +6 more
europepmc   +1 more source

KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis. [PDF]

Mol Cancer
Sun R, Huang Y, He H, Li Q, Wang L, Zhang G, Wei Z, Cao Y, Li J, Wang X, Yang F, Chen W, Li X, Yu J, Liu S, Lei C, Jiang Y, Peng Y, Su H, Gao Y, He W, Yang L, Liu J.   +22 more
europepmc   +1 more source